- Home
- ACRS vs CURR Comparison
ACRS vs CURR Comparison
Compare ACRS & CURR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- CURR
- Stock Information
- Founded
- ACRS 2012
- CURR 2013
- Country
- ACRS United States
- CURR Singapore
- Employees
- ACRS N/A
- CURR N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- CURR Business Services
- Sector
- ACRS Health Care
- CURR Consumer Discretionary
- Exchange
- ACRS Nasdaq
- CURR Nasdaq
- Market Cap
- ACRS 230.8M
- CURR 224.4M
- IPO Year
- ACRS 2015
- CURR N/A
- Fundamental
- Price
- ACRS $2.85
- CURR $2.76
- Analyst Decision
- ACRS Strong Buy
- CURR Strong Buy
- Analyst Count
- ACRS 5
- CURR 1
- Target Price
- ACRS $9.75
- CURR $3.50
- AVG Volume (30 Days)
- ACRS 1.4M
- CURR 2.2M
- Earning Date
- ACRS 11-06-2025
- CURR 11-01-2025
- Dividend Yield
- ACRS N/A
- CURR N/A
- EPS Growth
- ACRS N/A
- CURR N/A
- EPS
- ACRS N/A
- CURR N/A
- Revenue
- ACRS $15,742,000.00
- CURR $40,227,053.00
- Revenue This Year
- ACRS N/A
- CURR N/A
- Revenue Next Year
- ACRS N/A
- CURR $14.56
- P/E Ratio
- ACRS N/A
- CURR N/A
- Revenue Growth
- ACRS N/A
- CURR N/A
- 52 Week Low
- ACRS $1.05
- CURR $0.33
- 52 Week High
- ACRS $4.24
- CURR $7.08
- Technical
- Relative Strength Index (RSI)
- ACRS 67.71
- CURR 53.37
- Support Level
- ACRS $2.34
- CURR $2.29
- Resistance Level
- ACRS $2.57
- CURR $2.82
- Average True Range (ATR)
- ACRS 0.22
- CURR 0.38
- MACD
- ACRS 0.03
- CURR -0.07
- Stochastic Oscillator
- ACRS 96.18
- CURR 37.50
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.